Specifically, intraocular biopsy may identify Her2/neu-positive patients that may benefit from adjuvant anti-Her2/neu therapy [46] and estrogen or progesterone receptor-positive tumor cells that would respond to endocrine therapy administration [47]. This evidence concerns the gene ERBB2 and neoplasm.